Pharmaceuticals

HMNC Brain Health's new oral ketamine shows promise by minimizing side effects, but an unmet endpoint raises questions. Is this the key to at-home TRD care?

A UK spinout just raised £2M for an eye-drop that becomes a healing bandage on contact. This could disrupt a $12B market and offer hope for rare diseases.

With a promising osteoarthritis drug in late-stage trials, Levicept hires a CFO known for Nasdaq listings and M&A, signaling a major financial move.

Aligos Therapeutics secures a key partnership and regulatory fast-track in China, signaling a major financial and clinical validation for its novel HBV drug.

In an era of fleeting sponsorships, one pharma giant's three-decade investment in sportsmanship offers a powerful blueprint for building sustainable brand trust.

As Genomma Lab prepares its Q2 2026 earnings call, investors are watching if its famed operational network can navigate a weak Mexican market and margin pressures.

Vertex's new CF drug, ALYFTREK, clears a major hurdle in Canada, promising a once-daily treatment and new hope for patients previously left behind.

Shilpa Medicare and Orion Corp. partner on a nivolumab biosimilar, challenging Big Pharma and promising affordable access to a vital cancer immunotherapy.

With a new ADC expert as CMO, Corbus Pharmaceuticals is advancing its dual pipeline. This move signals a critical phase for its cancer drug and obesity therapy.

A new $200K award isn't just a grant; it's a strategic bet on systems engineering to fix a diagnostic pathway where 70% of lung cancer cases are found too late.

Invivyd's COVID-19 drug PEMGARDA loses its emergency status, sparking a high-stakes race for full approval and raising fears of a looming gap in patient care.

A South Korean biotech's diabetes drug finds new purpose in fighting FSHD, backed by a foundation's innovative funding model that could reshape rare disease R&D.

After a Health Canada-mandated pause, LSL's Steri-Med is near full remediation. This is more than a fix—it’s a calculated play for North American market leadership.

Australian biotech Immuron hires a top dealmaker to land a partner for its novel C. diff therapy. The goal: secure funding and unlock a potential $400M market.

UK biotech Ananda Pharma advances its MRX1 drug to Phase 2 trials, targeting a debilitating chemotherapy side effect with no current effective treatment.

Novartis's acquisition of Myricx Bio isn't just a deal. It's a story of academic grit, venture capital vision, and a new blueprint for patient-centric cancer therapy.

A new partnership aims to use tiny, fully human antibodies to shuttle drugs past the blood-brain barrier, a move that could unlock a new era of treatments.

Immunomic Therapeutics begins human trials for ITI-9001, an saRNA vaccine aiming to rewrite the immune response to Japanese cedar pollen allergy.

New data reveals a deep divide in who can access revolutionary weight-loss drugs, exposing a market that is both booming and profoundly under-penetrated.

An inside look at how Chengdu is pairing high-tech industrial might with aggressive global outreach to redefine itself as a critical node in tech and biotech.